ReviewNature reviews. Clinical oncology2019
Challenges to curing primary brain tumours.
3 registry-linked trialsAbstract readReview
In one paragraph
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 530 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
530citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Specific Model Electroacupuncture Stimulation Promotes Paclitaxel Delivery Across the BBB for Postoperative Glioma Patients: A Randomized Controlled Study
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Who cites it
530 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- The Three Pillars of Glioblastoma: A Systematic Review and Novel Analysis of Multi-Omics and Clinical Data.Cells · 2024Pooled it
- Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.Journal of neuro-oncology · 2024Pooled it
- FXYD5 promotes the growth of glioblastoma by targeting the PI3K/AKT/ACSL4 signaling axis.Oncology reports · 2026Article
- Improved Method for Obtaining Patient-Derived Glioblastoma Organoid and Primary Cells: A Generic and Simplified Approach for Intracranial Tumor With Minimized Input.CNS neuroscience & therapeutics · 2026Article
- Deepening the Understanding of Platelet-Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.Cancer chemotherapy and pharmacology · 2026Article
- Smart Surface-Engineered Mesoporous Silica Nanoparticles for Brain Tumor Therapy: Overcoming the Blood-Brain Barrier for Advanced Theranostics.AAPS PharmSciTech · 2026Review
- Mesenchymal tumors of the central nervous system: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- "It's My Wish, We Need This Program": Qualitative Reflections From People With High-Grade Brain Cancer Consenting to Postmortem Brain Donation.JCO oncology practice · 2026Article
- Acupuncture Attenuates Neuroinflammation Following Acute Cerebral Infarction by Downregulating SPP1 to Ameliorate Immunological Niches.Brain and behavior · 2026Article
- Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.Molecular diagnosis & therapy · 2026Review
- Label-free two-photon fluorescence lifetime imaging of FADHJournal of biomedical optics · 2026Article
- W-AGRU-Net: a dual-stream attention framework for robust brain tumor segmentation in clinical MRI imaging.Scientific reports · 2026Article
- Cellular adhesion-dependent 3D morphogenesis indicating brain tumor aggressiveness and chemosensitivity in spherical cavity culture.Experimental hematology & oncology · 2026Article
- EFEMP2 Is Associated with Shelterin-Related DNA Damage Repair, Immune Microenvironment Features, and Prognosis in Glioblastoma.Biomedicines · 2026Article
- Beyond the mutation: integrating radiogenomics, epigenetics, and immune signatures to overcome therapeutic resistance in CNS tumors: a narrative review.Annals of medicine and surgery (2012) · 2026Article
- Imaging, histological, and molecular characterization of a preclinical, orthotopic model of recurrent glioblastoma following image-guided laser ablation of the primary tumor.Journal of neurosurgery · 2026Article
- Patient experiences of tissue donation and digital consent support in primary craniospinal tumour research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Polyamines in CNS malignancies: positively charged culprits in the hijacking of neural and immune signaling pathways.Amino acids · 2026Review
470 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors.
Kenneth AldapeDepartment of Pathology, University Health Network, Toronto, Ontario, Canada.
Kevin M BrindleCRUK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
Louis CheslerThe Institute of Cancer Research, London, UK.
Rajesh ChopraThe Institute of Cancer Research, London, UK.
Amar GajjarDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Mark R GilbertCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Nicholas GottardoTelethon Kids Institute, Subiaco, WA, Australia.
David H GutmannDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Darren HargraveGreat Ormond Street Hospital for Children, London, UK.
Eric C HollandHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
David T W JonesPediatric Glioma Research Group, Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany.
Johanna A JoyceLudwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Pamela KearnsCancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Mark W KieranDana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
Ingo K MellinghoffHuman Oncology and Pathogenesis Program and Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Melinda MerchantOncology, AstraZeneca IMED Biotech Unit, Boston, MA, USA.
Stefan M PfisterDivision of Pediatric Oncology, Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany.
Steven M PollardCancer Research UK Edinburgh Centre and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
Vijay RamaswamyDepartment of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-6557-895X
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, CA, USA.
Giles W RobinsonDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7441-9486
David H RowitchDepartment of Paediatrics, University of Cambridge and Wellcome Trust-MRC Stem Cell Institute, Cambridge, UK.
John H SampsonThe Preston Robert Tisch Brain Tumor Center, Duke Cancer Center, Durham, NC, USA.
Michael D TaylorThe Arthur and Sonia Labatt Brain Tumour Research Centre and Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
Paul WorkmanThe Institute of Cancer Research, London, UK.
Richard J GilbertsonCRUK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK. richard.gilbertson@cruk.cam.ac.uk.ORCID http://orcid.org/0000-0001-7539-9472
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MThe DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MBrain Tumor Clinical and Clinical Research Program (Clinical Support Services)ZIDBC011642 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OZER, BYRAM · 2015 to 2025
$23.4MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MEnergy Stress in Brain Tumor Initiating Stem CellsR01NS089272 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICH, JEREMY N · 2014 to 2018
$1.7MStem Cell-Like Glioma Cells in AngiogenesisR01CA129958 · NCI · DUKE UNIVERSITY · PI RICH, JEREMY N · 2008 to 2012
$1.6MTGFbeta-PTEN Interactions in Glioma Biology & TherapyR01CA116659 · NCI · DUKE UNIVERSITY · PI RICH, JEREMY N · 2006 to 2010
$1.4MThe Roles of Osteonectin and Osteoactivin in GliomasK02NS047409 · NINDS · DUKE UNIVERSITY · PI RICH, JEREMY N. · 2004 to 2007
$612kCancer Research UK 15958Cancer Research UK 17242Cancer Research UK 17368Cancer Research UK 21992Cancer Research UK 22492Cancer Research UK 22897Cancer Research UK 26398Cancer Research UK 27413Cancer Research UK 28028Cancer Research UK 28289Cancer Research UK 28667Intramural NIH HHS Z99 CA999999Medical Research Council MC_PC_12009NCI NIH HHS P01 CA096832NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA116659NCI NIH HHS R01 CA129958NCI NIH HHS R35 CA197718NINDS NIH HHS K02 NS047409NINDS NIH HHS R01 NS089272
Abstract
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment.
Indexed as
Brain NeoplasmsHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.